NetworkNewsBreaks

MondaySep 18, 2023 11:41 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Interim Results from FIH Clinical Trial of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced the receipt of an interim report for the first-in-human (“FIH”) single ascending dose phase I clinical trial evaluating the company’s novel drug candidate. The interim blinded report for Lucid-21-302 (“Lucid-MS”), an orally administered treatment for multiple sclerosis ("MS"), was issued on Aug, 17, 2023, for the first four cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month. “We are…

Continue Reading

MondaySep 18, 2023 11:11 am

NetworkNewsBreaks – Upstream Experts Explore Ways for Brands to Expand Reach, Foster NFT community growth

Upstream, the revolutionary retail trading app for stocks and NFTs powered by Horizon Fintex and MERJ Exchange Limited, and key team members released the latest in its new Twitter Spaces series. The series, titled “Upstream Up Close,” features 10- to 15-minute conversations about NFTs, blockchain and trading on Upstream. The most recent release was the seventh episode, and the segment focused on how brands can grow their communities by tapping into NFT markets. Upstream officials participating in the release included Vanessa, Upstream head of marketing; Amanda, client success manager; and Anastasia and Fernanda, digital marketing specialists. Specifically, the group discussed…

Continue Reading

FridaySep 15, 2023 2:54 pm

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets. Lexaria has issued an exclusive, perpetual license to LEXX Nutra, allowing the use of DehydraTECH to create consumer packaged goods and/or intermediate ingredients composed of molecular compounds except those associated with nicotine or cannabis,” a recent article reads. “LEXX Nutra is also prohibited from using the licensing agreement for the manufacturing of…

Continue Reading

FridaySep 15, 2023 2:05 pm

NetworkNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) on Track to Create Independent CM Supply Chain

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for and separation and scalable production of rare earth elements (“REEs”) in Canada and the US, is moving to become a major leader in its sector. “Just recently, the company announced the closing of the first tranche of its previously announced private placement offering of units of the company, for aggregate gross proceeds of $4,409,500, in what is set to be a key catalyst in advancing its RapidSX(TM) REE commercial demonstration plant in Kingston, Ontario,” a recent article reads. “On June 6, Ucore announced that the U.S.…

Continue Reading

FridaySep 15, 2023 1:00 pm

NetworkNewsBreaks – Electronic Servitor Publication Network Inc. (XESP) Is Driving the ‘Future of Marketing’

Electronic Servitor Publication Network (OTC: XESP), a technology-oriented digital engagement and activation company, is pioneering the next step in the evolution of digital marketing with its Digital Engagement Engine(TM). “‘Our Digital Engagement Engine isn’t just another marketing tool. It’s a way to develop real connections with your target market. And it’s the future of marketing,’ explains the company. The Digital Engagement Engine is built on a robust stack of cutting-edge data analysis tools, smart technologies and microservices, which, combined, enable it to identify the narrowest of niches within a company’s target market, create content that meets customers’ exact needs, and…

Continue Reading

FridaySep 15, 2023 12:58 pm

NetworkNewsBreaks – Why Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

Renovaro BioSciences (NASDAQ: RENB), (formerly Enochian BioSciences Inc.), is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy. “Renovaro aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, as well as to potentially treat or cure serious infectious diseases… The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human phase I/IIa studies that are on track to start by mid-2024,” reads a recent article. “Renovaro’s proprietary, novel…

Continue Reading

FridaySep 15, 2023 12:49 pm

NetworkNewsBreaks – Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) Leveraging Guyana’s Growing Economy, Region’s Geological Prospects to Tap Opportunities

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) is strengthening its position as a leading gold explorer in the Guiana Shield amid continued economic growth and recovery in Guyana. “With that strong economic performance as a backdrop, Reunion Gold is positioning itself to leverage the strength of the economy while also contributing to the country’s growth. The company is a leading gold explorer in the Guiana Shield, which is made up of Guyana, Suriname and French Guiana,” a recent article reads. “‘The Guiana Shield remains one of the most prospective locations globally for the discovery of world-class orogenic gold deposits,’ the company…

Continue Reading

FridaySep 15, 2023 12:30 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”). The receipt of the ODD followed the FDA’s granting of Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. “With…

Continue Reading

FridaySep 15, 2023 12:15 pm

NetworkNewsBreaks – Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Tapping Emerging Technologies to Address Unmet Mobile Money Needs

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is working to develop a global financial technology ecosystem. “The company is keen on addressing unmet mobile money needs in developing and industrialized markets and making mobile transactions easier and more affordable. To turn its vision into a reality, FEXD is adopting emerging technologies like artificial intelligence (‘AI’),” a recent article reads. “Given the role AI has historically played in helping companies detect, measure and manage risk, it is still being called upon to deal with financial crime and cyber threats and detect fraud. In addition, and alongside these crucial applications of the technology,…

Continue Reading

FridaySep 15, 2023 12:14 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease… So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks…

Continue Reading